Get started
Author

Flávia Cavalcanti Balint

Observed names: F. BALINT, F. Balint, F. C. Balint, F. Cavalcanti Balint, Flavia Balint, Flavia C. Balint, Flavia Cavalcanti Balint, Flávia Balint, Flávia C. Balint
Institution: AC Camargo Hospital
Observed institution: AC Camargo Hospital
OpenAlex ID: A5096363373
Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study
2025 · Matheus de Oliveira Andrade, Isabella Gonçalves Gutierres, et al. · The Breast · 25
PDF
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer
2024 · Renata Colombo Bonadio, Isadora Martins de Sousa, et al. · npj Breast Cancer · 10
PDF
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study
2025 · Renata Colombo Bonadio, Monique Celeste Tavares, et al. · Breast Cancer Research and Treatment · 6
Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123
2026 · Mariana Carvalho Gouveia, Romualdo Barroso-Sousa, et al. · npj Breast Cancer · 2
PDF
Abstract PS4-07-04: Rare but Resistant: Neoadjuvant Chemoimmunotherapy in Special Histological Subtypes of Triple-Negative Breast Cancer — Insights from the Neo-Real/GBECAM-0123 Study
2026 · R. Barroso-Sousa, L. Testa, et al. · Clinical Cancer Research · 1
Real-world insights: Neoadjuvant KEYNOTE-522 regimen in triple-negative breast cancer patients with germline BRCA mutations.
2025 · Monique Celeste Tavares, Romualdo Barroso-Sousa, et al. · Journal of Clinical Oncology · 1
Real life comparison between doxorubicin and cyclophosphamide (AC) dose-dense (dd) and conventional dose AC in patients with triple negative breast cancer (TNBC) under neoadjuvant treatment.
2024 · Flavia Cavalcanti Balint, Monique Celeste Tavares, et al. · Journal of Clinical Oncology · 1
Role of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer treated with KEYNOTE-522 in real-world setting
2026 · Renata Colombo Bonadio, Flávia Cavalcanti Balint, et al. · npj Breast Cancer
PDF
Differential response and survival across rare histologic subtypes of triple-negative breast cancer following neoadjuvant chemo-immunotherapy
2026 · Romualdo Barroso-Sousa, Mariana Carvalho Gouveia, et al. · npj Breast Cancer
PDF
Impact of Race on Outcomes of Neoadjuvant Immunotherapy plus Chemotherapy for Triple-Negative Breast Cancer.
2026 · Patrick Vinicius Batista Cerqueira, Andre Luiz Cicilini, et al. · Brazilian Journal of Oncology
Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort
2026 · Monique Celeste Tavares, Flávia C. Balint, et al. · npj Breast Cancer
Functional domain disruption to define the molecular and clinical spectrum of germline RAD51 family variants in hereditary breast cancer (BC).
2026 · André Luiz Cicilini, Sandrine Caputo, et al. · Journal of Clinical Oncology
Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study
2026 · Matheus de Oliveira Andrade, Renata Colombo Bonadio, et al. · Breast Cancer Research and Treatment
Abstract PS4-07-11: Analysis of patients with triple-negative breast cancer and germline BRCA mutation undergoing neoadjuvant treatment following the keynote 522 protocol in real-world. Insights from the Neo-Real/GBECAM-0123 Study
2026 · M. C. Tavares, F. C. Balint, et al. · Clinical Cancer Research
Abstract PS2-02-17: The High Unmet Need of Patients with Early Relapse After the KEYNOTE-522 Regimen - Evidence from the Neo-Real/GBECAM-0123 Study
2026 · R. Colombo Bonadio, L. Lapuchesky, et al. · Clinical Cancer Research
Abstract PS4-07-10: The Relationship Between Tumor-Infiltrating Lymphocytes (TILs), Pathologic Complete Response, and Event-Free Survival in Patients with Early-Stage Triple-Negative Breast Cancer Treated with KEYNOTE-522 regimen in a Real-World Scenario
2026 · R. C. Bonadio, M. C. Tavares, et al. · Clinical Cancer Research
Abstract PS4-10-18: Tils as a predictor of response in triple-negative breast cancer: analysis of clinical and pathological outcomes in patients undergoing neoadjuvant chemotherapy based on the keynote-522 protocol in a brazilian cancer center
2026 · F. BALINT, G. de Almeida, et al. · Clinical Cancer Research
Abstract PS1-12-15: Metabolic complete response on 18FDG-PET-CT is a key predictor of Progression-Free Survival in metastatic luminal breast cancer treated with CDK4/6 inhibitors (CDK4/6i)
2026 · N. Soldi, V. Basílio, et al. · Clinical Cancer Research
574P PET-CT metabolic complete response: A key predictor of progression-free survival in metastatic luminal breast cancer treated with CDK4/6 inhibitors (CDK4/6i)
2025 · N. Machado Soldi, V. Primo Basilio de Souza, et al. · Annals of Oncology
Abstract P1-05-08: Germline Mutations in Early Triple-Negative Breast Cancer Brazilian Patients
2025 · Giulia Zanetta, Giulia K. Zanetta, et al. · Clinical Cancer Research
Abstract P5-11-30: Residual Cancer Burden (RCB) with Dose-Dense versus Every 3-Week AC regimen during Neoadjuvant Chemoimmunotherapy for Early-Stage Triple-Negative Breast Cancer – The Neo-Real Study
2025 · Renata Bonadio, Flávia Balint, et al. · Clinical Cancer Research
Abstract P5-09-18: Real-World Analysis of Patients with Triple-Negative Breast Cancer and Germline BRCA Mutation Undergoing Neoadjuvant Treatment Following the Keynote 522 Protocol
2025 · Monique Tavares, Flavia Cavalcanti Balint, et al. · Clinical Cancer Research
Abstract P2-11-14: Treatment Patterns and Safety of Adjuvant Therapy After Chemoimmunotherapy for Early-Stage Triple-Negative Breast Cancer in a Real-World Scenario: The Neo-Real Study
2025 · Renata Bonadio, Isadora Sousa, et al. · Clinical Cancer Research
Outcomes of elderly patients with early-stage triple-negative breast cancer treated with the KEYNOTE-522 regimen.
2025 · Renata Colombo Bonadio, Flavia Balint, et al. · Journal of Clinical Oncology
Pathologic response in er-low early-stage breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy
2025 · Renata Colombo Bonadio, Flávia Cavalcanti Balint, et al. · Brazilian Journal of Oncology
Works count: 29
Citation count: 46
H-index: 3
I10-index: 2
Year
Topic
Type